World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 4, August 2025, pages 342-346

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Tables

Table 1. Summary of Cohort Characteristics
 
Cohort characteristic (n = 14)N (%)
BMI: body mass index.
Age at diagnosis
  Median28.5
  Range21 - 57
  21 - 39 (young adults)12 (85.7)
  40 - 57 (adult)2 (14.3)
Biologic sex
  Male5 (35.7)
  Female9 (64.3)
BMI
  Median31.4
  Range21.8 - 49.0
  18.5 - 24.91 (7.1)
  25 - 29.94 (28.6)
  30 - 39.95 (5.7)
  ≥ 404 (28.6)
Ethnicity
  Hispanic14 (100)
Philadelphia chromosome
  Positive2 (14.3)
  Negative12 (85.7)

 

Table 2. Lab Values Obtained at Diagnosis Compared to Their Peak Values
 
Lab parameterAt diagnosisAt peak value
ALT: alanine aminotransferase; AST: aspartate aminotransferase; IQR: interquartile range.
ALT
  Median (IQR)54 (32, 107)453 (218, 643)
  Range15 - 19143 - 3491
AST
  Median (IQR)48 (38, 63)325 (216, 468)
  Range22 - 17551 - 3137
Total bilirubin
  Median (IQR)0.9 (0.7, 1.2)3.3 (2.8, 13.7)
  Range0.4 - 11.41.2 - 32.3

 

Table 3. Frequency of Adverse Events in Our Cohort
 
Adverse eventGrade 1Grade 2Grade 3Grade 4Grade 5
N (%)N (%)N (%)N (%)N (%)
All grades were assessed using CTCAE version 5.0 definitions. If a grade is not applicable to a particular adverse event, it is reported as “-”. CTCAE: Common Terminology Criteria for Adverse Events.
Allergic reaction/hypersensitivity1 (7%)0000
Hyperbilirubinemia2 (14%)5 (36%)1 (7%)5 (36%)0
Hypertriglyceridemia1 (7%)2 (14%)1 (7%)00
Pancreatitis-1 (7%)000
Thrombosis06 (43%)000
Transaminitis (ALT)1 (7%)1 (7%)10 (71%)2 (14%)0
Transaminitis (AST)1 (7%)2 (14%)9 (64%)2 (14%)0